Search results
Results from the WOW.Com Content Network
Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. [ 5 ] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication .
Ferric maltol was approved for medical use in the European Union in February 2016. [ 5 ] Ferric maltol was approved for medical use in the United States in July 2019, [ 4 ] [ 10 ] based on evidence from three clinical trials (trial 1/NCT01252221, trial 2/NCT01340872, [ 11 ] and trial 3/NCT02968368 [ 12 ] ). [ 3 ]
FDA approvals for these drugs could translate to billions of dollars for a few companies. 5 Biggest New Drug Approvals Potentially on the Way in 2019 Skip to main content
Alipogene tiparvovec (Glybera): AAV-based treatment for lipoprotein lipase deficiency (no longer commercially available); Axicabtagene ciloleucel (Yescarta): treatment for large B-cell lymphoma [1]
Diabetes treatment Mounjaro has been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far outstripped supply. The limited ...
Drug Manufacturer Indication Crizotinib: PF Prism: ALK-positive systemic anaplastic large cell lymphoma: Trastuzumab deruxtecan: Daiichi Sankyo: HER2-positive gastric or gastroesophageal junction adenocarcinoma, previously treated with trastuzumab: Umbralisib: TG Therapeutics: marginal zone lymphoma, previously treated with an anti-CD20-based ...
The FDA approval for sleep apnea is based on two company-sponsored trials encompassing about 470 participants, one in which patients were being treated with continuous positive air pressure, ...
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis. [7] [8] BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases. FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).